Retatrutide is an unapproved investigational chemical that cannot be used in drug compounding under federal law. It is not an active ingredient in any FDA-approved human medication and has not been determined to be safe or effective for any medical condition. The FDA has issued warning letters to telehealth companies, chemical distributors, and compounding pharmacies marketing unapproved retatrutide to consumers with administration or dosage instructions.
- Chemical identity, purity percentage, or active mass of any unapproved research vial.
- Sterility, endotoxin levels, or contamination risk of liquid solutions.
- Clinical dosing schedules, titration advice, or medical treatment protocols.
- Personal guidance on experimental compound administration.
This tool converts volumetric liquid measurements and syringe tick marks only. It does not provide medical guidance, dosing schedules, or clinical administration protocols. Review our Medical & Research Disclaimer.
FDA Regulatory Determination and Compounding Prohibitions
As of November 8, 2026, the U.S. Food and Drug Administration (FDA) maintains a clear regulatory stance regarding retatrutide: it cannot be used in compounding under federal law. Furthermore, retatrutide is not a component of any FDA-approved drug product and has not been evaluated or determined to be safe or effective for any medical condition or human use. The FDA has actively issued formal warning letters to telehealth entities, chemical distributors, and compounding facilities that market unapproved retatrutide products to consumers or supply the active pharmaceutical ingredient with suggested dosing instructions.
The FDA has published an identical regulatory determination for cagrilintide, confirming that cagrilintide likewise cannot be legally used in drug compounding under federal law, is not an approved active pharmaceutical ingredient, and lacks FDA safety or efficacy evaluation.
What a Calculator Cannot Verify About Any Vial
When individuals search for a retatrutide dosage calculator or reconstitution tool, they often seek to translate vial milligrams into liquid volume and syringe unit tick marks. However, mathematical volume conversion cannot verify what is physically inside an unapproved research vial. An online mathematical calculator cannot confirm compound identity, ensure sterility, test biological potency, or verify chemical concentration.
Even when analytical paperwork is provided by an online vendor, testing sheets possess substantial real-world limits. As detailed in our comprehensive guide on what a certificate of analysis can and cannot tell you, standard batch certificates cannot confirm whether a specific distributed vial was maintained in sterile conditions, protected from thermal degradation, or packaged without harmful contaminants. Review our glossary definition of analytical testing for more details.
Investigational Status in Clinical Research
Retatrutide (LY3437943) is an investigational synthetic peptide that acts as an agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is currently being investigated in registered, multicenter human clinical trials to evaluate its pharmacokinetic, safety, and metabolic profiles, as documented in peer-reviewed clinical trial reports published in The New England Journal of Medicine (DOI: 10.1056/NEJMoa2301972).
Because retatrutide remains an active investigational drug undergoing formal phase 3 clinical evaluation, no approved consumer dosage guidelines exist. This platform makes zero therapeutic, efficacy, or safety claims regarding clinical trial outcomes.
Reporting Adverse Reactions and Seeking Care
Individuals enrolled in clinical trials must direct all medical, administration, or protocol questions strictly to their authorized study team. Patients seeking medical treatment for metabolic conditions should consult a licensed healthcare provider regarding FDA-approved incretin medications (for printed-concentration arithmetic on approved or pharmacy-dispensed incretins, see our Semaglutide calculator and Tirzepatide calculator).
Consumers, patients, and healthcare providers who encounter adverse events, dosing mistakes, or substandard products involving unapproved or compounded peptide products can report them directly to the federal government via the FDA MedWatch Adverse Event Reporting Program.
Educational Scope
This status summary is provided for public informational and regulatory transparency purposes. For broader reconstitution arithmetic on how liquid volumes map to standard U-100 syringe units, visit our reconstitution FAQ directory or access our general peptide calculator tool. Review our complete Medical and Research Disclaimer for site-wide terms.
Scientific & Regulatory References
View Full Sources Registry→The mathematical formulas on this page are deterministic volumetric conversions. Non-mathematical parameters, regulatory status notes, and chemical safety guidelines are referenced directly to the primary sources cataloged below:
- [1]FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration (FDA CDER)•Type: fda communication•Verified: 2026-11-08
FDA safety alert detailing risks of unapproved compounded GLP-1 drugs, dosing errors, lack of pre-market review, improper cold-chain shipping temperatures, and recommendation to discard multi-dose sterile vials 28 days after first puncture.
- [2]Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialThe New England Journal of Medicine (NEJM / PubMed PMID: 37364315)•Type: peer reviewed•DOI: 10.1056/NEJMoa2301972•Verified: 2026-11-08
Phase 2 randomized, double-blind, placebo-controlled trial evaluating retatrutide in adults with obesity (PMID: 37364315).